Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    Why did this record match?
    Reference Devices :

    K213937

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Halyard Purple Nitrile* Powder-Free Exam Gloves, Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, Simulated Gastric Acid and Fentanyl in Simulated Gastric Acid are disposable devices intended for medical purposes that are worn on the examiner's hand to prevent contamination between patient and examiner. These gloves were tested for use with the following chemotherapy drugs and Fentanyl Citrate and Gastric Acid as per ASTM -D6978-05 :

    The following chemotherapy drugs and concentration had NO breakthrough detected up to 240 minutes: Azacitidine (25 mg/ml) Bendamustine HCl (5 mg/ml) Bleomycin Sulfate (15 mg/ml) Bortezomib (1 mg/ml) Busulfan (6 mg/ml) Capecitabine (26 mg/ml) Carboplatin (10 mg/ml) Carlzomib (2 mg/ml) Cetuximab (2 mg/ml) Chloroquine (50 mg/ml) Cisplatin (1 mg/ml) Cladribine (1 mg/ml) Cyclophosphamide (20 mg/ml) Cyclosporin A (100 mg/ml) Cytarabine (Cytosine) (100 mg/ml) Cytovene (Ganciclovir) (10 mg/ml) Dacarbazine (DTIC) (10 mg/ml) Dactinomycin (0.5 mg/ml) Daunorubicin HCl (5 mg/ml) Decitabine (5 mg/ml) Docetaxel (10 mg/ml) Doxorubicin HCl (2 mg/ml) Epirubicin HCl (Ellence) (2 mg/ml) Etoposide (Toposar) (20 mg/ml) Fludarabine (25 mg/ml) 5-Fluorouracil (50 mg/ml) Fulvestrant (50 mg/ml) Gemcitabine (38 mg/ml) Idarubicin (1 mg/ml) Ifosfamide (50 mg/ml) Irinotecan HCl (20 mg/ml) Leuprolide Acetate Salt (5 mg/ml) Mechlorethamine HCl (1 mg/ml) Melphalan (5 mg/ml) Methotrexate (25 mg/ml) Mitomycin C (0.5 mg/ml) Mitoxantrone (2 mg/ml) Oxaliplatin (5 mg/ml) Paclitaxel (6 mg/ml) Pemetrexed (25 mg/ml) Raltitrexed (0.5 mg/ml) Retrovir (10 mg/ml) Rituximab (10 mg/ml) Temsirolimus (25 mg/ml) Topotecan HCl (1 mg/ml) Triclosan (2 mg/ml) Trisenox (1 mg/ml) Vinblastine Sulfate (1 mg/ml) Vincristine (1 mg/ml) Vinorelbine (10 mg/ml) Zoledronic Acid (0.8 mg/ml)

    The following chemotherapy drugs and concentration showed breakthrough detected in less than 90 minutes: Carmustine (3.3 mg/ml) No breakthrough up to 55.3 minutes. Thiotepa (10 mg/ml) No breakthrough up to 78.8 minutes. Warning- Not for use with Carmustine and ThioTEPA

    The following hazardous drugs (opioids) and concentration had NO breakthrough detected up to 240 minutes:

    Fentanyl Citrate Injection (100 mcg/2 ml)

    Simulated Gastric Acid Fluid/Fentanyl Citrate Injection Mix (50/50 Solution) (50 mcg/2 ml)

    Device Description

    The Halyard Purple Nitrile* Powder-Free Exam Gloves, Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, Simulated Gastric Acid and Fentanyl in Simulated Gastric Acid are disposable, 9.5 " purple-colored, chlorinated, nitrile, powder-free, textured fingertip, ambidextrous, non-sterile patient examination gloves.

    AI/ML Overview

    Here's a summary of the acceptance criteria and the study that proves the device meets them, based on the provided text:

    Device: Halyard Purple Nitrile* Powder-Free Exam Gloves, Low Dermatitis Potential, Tested for Use with Chemotherapy Drugs, Fentanyl Citrate, Simulated Gastric Acid and Fentanyl in Simulated Gastric Acid (K241909).

    1. Table of Acceptance Criteria and Reported Device Performance:

    TestStandardAcceptance CriteriaReported Device Performance
    DimensionsASTM D 6319Length ≥230 mmMeets requirements
    Palm Width: XS: 60-80mm, S: 70-90mm, M: 85-105mm, L: 100-120mm, XL: 110-130mm, XXL: 120-140mmMeets requirements
    Finger, Palm, Cuff thickness ≥0.05 mmMeets requirements
    Physical PropertiesASTM D 6319AQL 4.0Meets requirements
    Before Aging: Tensile Strength: ≥14 MPa, Ultimate elongation: ≥500%Meets requirements
    After Aging: Tensile Strength: ≥14 MPa, Ultimate elongation: ≥400%Meets requirements
    Freedom from PinholesASTM D 6319, ASTM D 5151AQL 2.5%, No leakageMeets requirements
    Powder FreeASTM D 6124, ASTM D 6319≤ 2 mg / gloveMeets requirements (average of 0.4 mg/glove)
    Test for irritationISO 10993, Part 23Grade 1Under the conditions of the study, the device is not an irritant.
    Test for acute systemic toxicityISO 10993, Part 11No animals treated with test extracts exhibit greater reaction than control animals.Under the conditions of the study, no evidence of acute systemic toxicity.
    Test for skin sensitizationISO 10993, Part 10Grade
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1